Compare CNDT & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNDT | IRWD |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 448.6M | 520.6M |
| IPO Year | N/A | 2010 |
| Metric | CNDT | IRWD |
|---|---|---|
| Price | $2.07 | $4.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.12 |
| AVG Volume (30 Days) | 1.2M | ★ 7.5M |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | ★ $3,072,000,000.00 | $338,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.37 | $37.22 |
| P/E Ratio | ★ N/A | $25.64 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.72 | $0.53 |
| 52 Week High | $4.90 | $5.78 |
| Indicator | CNDT | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 56.12 | N/A |
| Support Level | $1.98 | N/A |
| Resistance Level | $2.10 | N/A |
| Average True Range (ATR) | 0.08 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 90.38 | 0.00 |
Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments namely Commercial Industries which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas of which the majority of revenue is generated in the United States.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.